Ngo-Hamilton explains
Ozempic and similar GLP-1 receptor agonists have become popular weight loss tools, but MS patients require a more thoughtful, personalized approach to determine safety and compatibility with their neurological condition
Only a minority of studies, that is, four in Parkinsons disease 52,53,54,55 , five in substance-use disorders 111,113,115,116,117 , one in psychotic disorders 144 and two in mood disorders 178,179,182 , assessed the cognitive and mental health effects of GLP-1RAs in non-diabetic, non-obese populations
The trials show that people who stop suddenly without support regain a significant proportion of the weight lost 10
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study